Skip to main content
Apply for Grants

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (1914${count})

  • Biosample Use Program, 2020
    Metabolomic Analysis of Penetrance, Prognosis and Tracking Biomarkers of LRRK2 PD

    Study Rationale:
    Mutations in a gene called LRRK2 can cause Parkinson's disease but only a quarter to half of the people who carry one of these mutations will actually develop Parkinson’s in their...

  • Research Grant, 2020
    More Than Pretty Pictures: Ion Imaging of Lipid Content and Flux Kinetics in Models of Parkinson’s Disease

    Study Rationale:
    Glycosphingolipids are natural cellular fats. They are components of cellular membranes that fulfill multiple functional roles, from cell structure and transport to signaling. The...

  • Therapeutic Pipeline Program, 2020
    Developing TMEM175 Activators as Therapeutics for Parkinson's Disease

    Study Rationale:    
    Our aim is to develop a drug that will slow or stop the progression of Parkinson’s disease in patients who carry a mutation in the TMEM175 gene. The TMEM175 gene produces a...

  • Research Grant, 2020
    Parkinson’s Disease with Mild Cognitive Impairment Treated with a Nicotinic Agonist Drug

    Study Rationale:
    Parkinson’s disease with mild cognitive impairment (PD-MCI) is common, has important clinical consequences, and there is currently no treatment available. The underlying pathology of...

  • Therapeutic Pipeline Program, 2020
    Identification and Characterization of Small Molecule Activators of ATP13A2 for Parkinson’s Disease Therapy

    Study Rationale:
    In Parkinson’s disease, neurons degenerate because of a disturbed function of the lysosomes and mitochondria. The lysosomal transporter ATP13A2 (PARK9) is genetically implicated in...

  • Target Validation, 2020
    Identification of apoptosis-associated speck-like protein containing a CARD (ASC) as a disease-modifying therapeutic target in Parkinson’s disease

    Study Rationale:
    Inflammasomes are large multiprotein complexes that play a central role in the innate immune system, the body’s first line of defense against microbes. Inflammasomes are key drivers...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.